Boston Scientific Corporation $BSX Shares Sold by GC Wealth Management RIA LLC

Key Points

• GC Wealth Management cut its Boston Scientific stake by 74.5% in Q4, selling 19,045 shares and leaving it with 6,530 shares worth about $623,000.
• Institutional activity is heavy and mixed: several large managers (Parnassus, Egerton, Jennison, Marshall Wace) substantially increased holdings and institutional ownership is ~89.07%, while some funds have sold or trimmed exposure.
• Operational and sentiment notes: Boston Scientific beat Q1 estimates (EPS $0.80 vs. $0.79) and gave Q2/FY2026 guidance, but analysts have trimmed ratings/targets and CEO Michael Mahoney sold 160,901 shares (~$15.0M), adding to mixed market sentiment and legal overhang from class‑action filings.

GC Wealth Management RIA LLC cut its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 74.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,530 shares of the medical equipment provider's stock after selling 19,045 shares during the quarter. GC Wealth Management RIA LLC's holdings in Boston Scientific were worth $623,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parnassus Investments LLC raised its position in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider's stock worth $672,128,000 after acquiring an additional 6,868,459 shares during the last quarter. Egerton Capital UK LLP raised its position in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock worth $518,660,000 after acquiring an additional 3,671,548 shares during the last quarter. Jennison Associates LLC raised its position in Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider's stock worth $482,170,000 after acquiring an additional 2,823,744 shares during the last quarter. Alphinity Investment Management Pty Ltd acquired a new position in Boston Scientific during the fourth quarter worth about $252,918,000. Finally, Marshall Wace LLP raised its position in Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider's stock worth $956,680,000 after acquiring an additional 2,301,383 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wall Street Zen cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Daiwa Securities Group cut Boston Scientific from a "strong-buy" rating to a "hold" rating in a report on Wednesday. Robert W. Baird cut their price target on Boston Scientific from $86.00 to $78.00 and set an "outperform" rating for the company in a report on Thursday, April 23rd. Evercore cut their price target on Boston Scientific from $112.00 to $96.00 and set an "outperform" rating for the company in a report on Thursday, February 5th. Finally, National Bank Financial set a $115.00 price target on Boston Scientific in a report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $93.91.

Boston Scientific Stock Performance

Boston Scientific stock opened at $57.69 on Friday. The firm has a market capitalization of $85.74 billion, a P/E ratio of 24.14, a PEG ratio of 1.05 and a beta of 0.78. The stock has a fifty day moving average price of $67.06 and a 200 day moving average price of $84.72. Boston Scientific Corporation has a 52 week low of $56.05 and a 52 week high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The business's quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: New clinical data and procedure adoption: A Reuters note highlighted that a procedure using a Boston Scientific device outperformed drug therapy for a heart‑rhythm indication, supporting device demand and reimbursement relevance. This is a clear product/market tailwind if adoption continues. Procedure using Boston Scientific device tops medication
• Positive Sentiment: Supportive TV commentary: Jim Cramer said he thinks Boston Scientific "can come back," a sentiment that can boost retail interest and short‑term buying flows. Jim Cramer on Boston Scientific
• Positive Sentiment: Institutional buying signal: Lone Pine Capital (Stephen Mandel) opened a new position, signaling selective hedge‑fund interest in BSX. Large manager activity can be supportive for the stock if it continues. Stephen Mandel opens new position
• Neutral Sentiment: Investor attention piece: Zacks flagged BSX as drawing investor attention, a sign of increased search/interest but not necessarily directional news. Monitor volume and follow‑through. Zacks: BSX attracting investor attention
• Neutral Sentiment: Ticker confusion: A GlobeNewswire item about Belo Sun TSX: BSX appears in feeds — note this is a different company and unrelated to Boston Scientific NYSE: BSX. Don’t conflate the two. Belo Sun Provides Update (unrelated ticker)
• Neutral Sentiment: Market commentary roundup: Aggregated articles (MSN/Yahoo) are weighing bullish vs bearish views; these are useful for sentiment tracking but contain no single material disclosure. MSN: Wall Street bullish or bearish?
• Negative Sentiment: Class‑action filings and lead‑plaintiff deadline (May 4): Multiple law firms and plaintiff notices allege disclosure issues around U.S. electrophysiology sales and invite claims—this increases legal overhang and potential settlement risk. Monitor filings and reserve/expense guidance. Securities fraud lawsuit alert
• Negative Sentiment: Analyst downgrades and lower targets: Daiwa cut BSX to "hold" and at least one outlet reports an ~11% cut to the price target — these reduce near‑term analyst support and can pressure sentiment. Daiwa downgrade / analyst action
• Negative Sentiment: Fund selling and estimate cuts: Polen Capital disclosed it sold its stake citing competition concerns, and Erste Group trimmed FY2026/27 EPS forecasts — both items point to investor wariness on competitive pressure and margin/earnings outlook. Polen sold stake

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.34% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.